Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

AURORA, Ontario, June 15 /PRNewswire/ -- Helix BioPharma Corp. ("Helix" or the "Company"), (TSX, FSE: "HBP") today announced its product development progress, quarterly highlights and financial results for the third quarter of fiscal 2009, ended April 30, 2009.

THIRD QUARTER HIGHLIGHTS AND PRODUCT DEVELOPMENT UPDATE

U.S. Registration Statement

Helix's 20-F registration statement filed with the U.S. Securities and Exchange Commission became effective during the quarter.

BioFinance 2009 Investor Conference Presentation

John Docherty, president and chief operating officer, presented at the BioFinance 2009 Investor Conference, where he provided an overview of the Company's leading technology platforms, DOS47(TM) and Biphasix(TM) and the Company's current product development programs, L-DOS47 and Topical Interferon Alpha-2b.

L-DOS47 Product Development Update

Over the past quarter, Helix has continued to advance towards initiating Phase I/II-level human clinical studies with L-DOS47. It has submitted a formal meeting request to the FDA for a pre-IND meeting, in anticipation of a future IND filing. The Company has also continued to advance its GMP manufacturing scale-up program with the successful production of engineering batches of L-DOS47, and is currently making preparations to produce its first clinical batch of GMP product to be used in its initial human trials.

Helix plans to file IND/CTA applications in North America and Europe, respectively, to seek permission to initiate Phase I/II studies. Due to recent challenges in successfully producing GMP engineering batches to date, including third party scheduling and technical issues, the Company has revised its estimated date of IND filing. Based on the estimated delay for completing the remaining program activities, and assuming successful and timely completi
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
(Date:8/26/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended June 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... to our Oral Amp B program, rapidly advancing ... Andrew Rae , President & CEO of ...
(Date:8/26/2015)... MIAMI , Aug. 26, 2015  The ... at the University of Miami Miller School of ... its clinical trial to test for the first ... was successfully completed.  This FDA approved Phase I/II ... islet transplantation and is an important first step ...
(Date:8/26/2015)... 26, 2015 Israel Proves Its Place in ... st place  Wayerz comes in 5 th ... by venture capital fund JVP, with Chinese consulting firm ... China , Israel , ... Impressive achievement for the Israeli representatives in the final round ...
Breaking Biology Technology:Marken Ensures Safe Transportation Of Select Agents And Toxins 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
... Third Quarter 2008 GAAP Earnings Per Share were $1.09, an Increase from ... Per Share of $0.18, Full Year Revenue Guidance Raised from $14.6 Billion ... $14.9 Billion ... to $4.45 - $4.55, THOUSAND OAKS, Calif., Oct. 22 Amgen (Nasdaq:,AMGN) ...
... the leader in,automated proofreading solutions for the pharmaceutical ... pharmaceutical companies have selected Global,Vision to help them ... from,occurring in their packaging process. The integration of ... quality issues and,costs, along with speeding up product ...
... antagonist now approved in single-use ... ... US, Inc. today,announced that the U.S. Food and Drug Administration ... hydrochloride,injection) Premixed in 5% Dextrose. Discovered and developed by Astellas,Vaprisol, ...
Cached Biology Technology:Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 2Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 3Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 4Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 5Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 6Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 7Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 8Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 9Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 10Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 11Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 12Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 13Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 14Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 15Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 16Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 17Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 18Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 19Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 20Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 21Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 22Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 23Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23 24Global Vision Recognized for Helping Pharmaceutical Companies Achieve Complete Artwork and Copy Accuracy in their Packaging Process 2FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 2FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 3FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 4
(Date:8/5/2015)... New York , August 5, 2015 ... market report titled "Facial Recognition Market - Global Industry ... 2022", the global market for facial recognition is forecast ... is driven by increased demand for surveillance systems by ... the rising number of crimes and terrorist activities across ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... a cellular trigger that normally regulates replenishment of ... in mice. Removing the abnormal stimulation causes the ... a possible treatment for the lethal, aggressive brain ... Erica L. Jackson, of the University of California, ...
... published by BioMed Central, the open access publisher, received ... in the top 10 of their 2005 Journal Citation ... Factor exceeding 3.00, open access journals are confirmed as ... Central's flagship title covering biology in the post-genomic era, ...
... scientists working at the epicenter of the AIDS epidemic ... virus (HIV) "exhausts" killer T cells that would otherwise ... simply "turn off" fully functional T cells by flipping ... studies, however, the scientists showed that they could reinvigorate ...
Cached Biology News:Possible birthplace of malignant brain tumors identified 2Impressive new Impact Factors for BioMed Central's open-access journals 2How HIV 'exhausts' killer T cells 2How HIV 'exhausts' killer T cells 3How HIV 'exhausts' killer T cells 4